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Abstract 
Background: The aim of this study was to investigate the efficacy and safety of 
gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract 
cancer.  
Patients and Methods: A retrospective study was performed on 15 consecutive patients. 
Gemcitabine was administered intravenously at 1,000 mg/m2 on days 8 and 15. Oral S-1 
(60 mg/m2 in 2 divided doses) was given daily for the first 2 weeks, followed by 1 week of 
rest. This 3-week course of treatment was repeated. The primary endpoint was response 
rate, and the secondary endpoints were overall survival, progression-free survival, and 
safety.  
Results: The overall response rate was 26.7%, and the disease control rate was 73.4%. 
The overall survival was 12.0 months (95% CI, 9.5–14.5 months), and the progression-free 
survival was 8.0 months (95% CI, 4.3–11.7 months). Adverse events of grade 3 or 4 
occurred in 33.3%, and the major grade 3/4 toxicities were anemia (20.0%), leukopenia 
(13.3%), and anorexia (13.3%).  
Conclusion: Gemcitabine and S-1 combination chemotherapy is effective and safe in 
patients with advanced biliary tract cancer.  











Biliary tract cancer is uncommon but has a poor prognosis in Western countries [1]. In 
Japan, however, it is a common cause of death, accounting for an estimated 16,000 deaths 
annually [2]. While surgery remains the only curative treatment, most patients are 
diagnosed at an unresectable advanced stage of disease. 
A previous report showed a superior survival time among patients with biliary tract 
cancer who were treated with 5-fluorouracil-based regimens, compared with best-
supportive care [3]. Recently, many phase II studies have been reported for various 
regimens, such as gemcitabine, S-1, capecitabine, cisplatin, and oxaliplatin [4–7]. 
According to a pooled analysis of 112 trials, Eckel and Schmid [8] suggested that the 
combination of gemcitabine and platinum compounds represents the provisional 
standard for chemotherapy in patients with advanced biliary tract cancer. Furthermore, a 
prospective multicenter phase III trial of gemcitabine and cisplatin versus gemcitabine 
(ABC-02 study) was reported in 2009, and a statistically significant improvement in 
survival was observed among patients treated with gemcitabine and cisplatin, compared 
with gemcitabine alone [9]. 
S-1 (TS-1; Taiho Pharmaceutical) is an oral fluoropyrimidine anticancer drug designed 
to enhance the anticancer activity and to reduce the gastrointestinal toxicity of 
fluorouracil. S-1 consists of tegafur and 2 biochemical modulators, 5-chloro-2,4-
dihydroxypyridine and potassium oxonate (molar ratio: 1:0.4:1). Previous phase II studies 
of S-1 monotherapy have reported overall response rates of 17.2 to 35.0% with tolerable 
toxicity for patients with advanced biliary tract cancer [6, 7]. Therefore, S-1 may be a key 
antitumor agent for these patients. Meanwhile, gemcitabine and S-1 combination 
chemotherapy also showed promising results, with a 34% response rate and mild toxicity 
for patients with advanced biliary tract cancer [10]. 
Based on these results, we studied the efficacy and safety of gemcitabine and S-1 
combination chemotherapy in patients with advanced biliary tract cancer. The primary 
endpoint was the response rate. The secondary endpoints were overall survival (OS), 
progression-free survival (PFS), and toxicity. 
Patients and Methods 
Eligibility Criteria 
This is a single-center, retrospective study. Eligible patients had to have (i) histologically or 
cytologically confirmed adenocarcinoma of the biliary tract; (ii) an Eastern Cooperative Oncology 
Group performance status of 2 or less; (iii) an age of 20 years or older; (iv) a measurable tumor (in 
patients who had unresectable or recurrent disease); (v) an expected survival of at least 3 months; (vi) no 
previous treatment for any cancer; (vii) adequate organ function (hemoglobin >9 g/dl, leukocyte count 
>3,000/μl, platelet count >100,000/μl; transaminases <2.5 times the upper limit of normal, total bilirubin 
<3 times the upper limit of normal; and a serum creatinine level no greater than the upper limit of 
normal). Written informed consent was obtained from all the patients before enrollment in the study.  











Gemcitabine was administered intravenously at a dose of 1,000 mg/m
2 as a 30-min infusion on days 
8 and 15. Oral S-1 (60 mg/m
2 in 2 divided doses) was given daily for the first 2 weeks, followed by 1 
week of rest. In the case of grade 3/4 hematological toxicity or grade 2 or higher non-hematological 
toxicity, treatment was delayed until recovery to a grade 1 toxicity level. The dose of gemcitabine was 
not reduced during the next course. If further toxicity was observed, the gemcitabine dose was reduced 
to 800 mg/m
2.
 This 3-week course of treatment was repeated until the appearance of unacceptable 
toxicity, withdrawal of consent by the patient, or the detection of progressive disease. 
Statistical Analysis 
The primary endpoint was overall response rate. Hematologic tests were performed, and clinical 
symptoms were assessed biweekly. Tumors were evaluated every 2 months using imaging studies 
(computed tomography, magnetic resonance imaging, chest radiography, ultrasonography). The 
Response Evaluation Criteria in Solid Tumors (RECIST) were used to assess all the images. Secondary 
endpoints were OS, PFS and toxicity. OS was defined as the period between the date of the start of the 
first cycle of chemotherapy and the date of death. Deaths from other diseases were considered events, 
and data on patients without an event were censored as of the date of the final evaluation. PFS was 
defined as the period between the date of the start of treatment and the date on which the first evidence 
of disease progression was obtained. OS and PFS were calculated using the Kaplan-Meier method. 
Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria 
(NCI-CTC), version 2.0 [11]. 
Results 
Patient Characteristics 
From January 2008 to June 2010, 15 patients (median age 70 years; range 53–79 years) 
with locally advanced or metastatic biliary tract cancer were enrolled. The patient 
characteristics are summarized in table 1. There were 10 men (66.7%) and 5 women 
(33.3%). All patients had a performance status of 0 or 1. The primary tumor site was the 
gallbladder in 8 patients (53.3%), the extrahepatic biliary tract in 4 patients (26.7%), the 
intrahepatic biliary tract in 2 patients (13.3%), and the ampulla of Vater in 1 patient 
(6.7%). Twelve patients (80.0%) had undergone a resection of the primary tumor with 
curative intent. 
Response and Survival 
The responses of all 15 patients are summarized in table 2. None of the patients 
achieved a complete response. Four patients (26.7%) achieved partial response. The 
overall response rate was 26.7%. An additional 7 patients (46.7%) had stable disease; 
consequently, the disease control rate was 73.4%. Progressive disease was noted in 4 
patients (26.6%); all of these patients died within 7 months. According to the tumor site, 
the overall response rate and the disease control rate were 25.0 and 62.5% for the patients 
with gallbladder cancer and 28.6 and 71.4% for the patients with non-gallbladder cancer, 
respectively. 
The median OS was 12.0 months (95% CI, 9.5–14.5 months) (fig. 1), and the median 
PFS was 8.0 months (95% CI, 4.3–11.7 months) (fig. 2). The OS and PFS for the patients  










with gallbladder cancer were 9.0 and 5.0 months, respectively, while the OS and PFS for 
non-gallbladder cancer had not yet been reached. 
Toxicity 
A total of 109 cycles of gemcitabine and S-1 combination chemotherapy were 
administered. The median number of cycles administered per patient was 7 (range 3–15 
cycles). There were no treatment-related deaths. The most common hematologic 
toxicities were leukopenia (10/15, 66.7%) and anemia (9/15, 60.0%). The most common 
non-hematological toxicities were fatigue (5/15, 33.3%) and anorexia (5/15, 33.3%). Grade 
3 or 4 toxicities were observed in 5 of the 15 patients (33.3%), and the major grade 3/4 
toxicities were anemia (3/15, 20.0%), leukopenia (2/15, 13.3%), anorexia (2/15, 13.3%), 
nausea (1/15, 6.7%), and dehydration (1/15, 6.7%). The dose intensities of gemcitabine 
and S-1 were 90.6 and 97.3%, respectively. 
Discussion 
Until the ABC-02 study was reported in 2009 [9], no standard chemotherapy for 
advanced biliary tract cancer existed. The median OS of the gemcitabine and cisplatin-
treated group was longer than that of the gemcitabine-treated group (11.7 vs. 8.3 months, 
p = 0.002). The PFS of the gemcitabine and cisplatin-treated group was also longer than 
that of the gemcitabine-treated group (8.5 vs. 6.5 months, p = 0.003). After this study was 
reported, gemcitabine and cisplatin began to become the new worldwide standard of care 
for advanced biliary tract cancer. 
In our study, gemcitabine and S-1 combination chemotherapy achieved a disease 
control rate (partial response: 26.7%, stable disease: 46.7%) of 73.4%, an OS of 12.0 
months, and a PFS of 8.0 months. Sasaki et al. [10] reported that the OS and PFS of 
gemcitabine and S-1 chemotherapy were 11.6 months and 5.9 months, respectively. 
Furuse et al. [6] and Sasaki et al. [7] evaluated the effectiveness of S-1 monotherapy, and 
reported an OS and PFS of 9.4 and 3.7 months (Furuse et al.) and 8.7 and 4.2 months 
(Sasaki et al.), respectively. Based on these results, the addition of gemcitabine to S-1 
monotherapy may be more promising as a superior regimen, compared with S-1 
monotherapy. 
Regarding the primary tumor site, no difference in tumor response was observed in 
this trial, although the OS and PFS of patients with gallbladder cancer tended to be 
shorter than those of patients with non-gallbladder cancer. Several clinical trials have 
shown a statistically significant difference in the OS and PFS of patients with gallbladder 
cancer and those with non-gallbladder cancer [6, 12–14]. The reason for this is not clear, 
but the heterogeneous nature of gallbladder cancer and non-gallbladder cancer may be 
one explanation. Different expressions in cell cycle-regulatory proteins have been 
observed in biliary tract adenocarcinomas according to tumor location and morphology. 
Jarnagin et al. [15] suggested that the different OS according to tumor site was at least 
partly related to a significant difference in p27 expression. Gallardo et al. therefore 
suggested the necessity of individual trials, since gallbladder cancer has a more aggressive 
progression than non-gallbladder cancer [16]. However, the relationship between the 
response to chemotherapy and tumor location remains unclear.   










Most adverse events were grade 1 or 2. The incidence of grade 3 or 4 hematologic 
toxicities were less than 20%, which was equivalent or inferior to that of previous phase II 
or III studies of gemcitabine-based combination chemotherapy [4, 5, 9, 10]. According to 
the incidence of non-hematological toxicities, the grade 3 or 4 toxicities were less than 
13.3%; moreover, peripheral sensory neuropathy and hand-foot syndrome were especially 
uncommon, while these toxicities were commonly observed during treatment with 
oxaliplatin and capecitabine. Therefore, this combination chemotherapy was relatively 
well tolerated. 
In conclusion, our study indicates that gemcitabine and S-1 combination 
chemotherapy for the treatment of advanced biliary tract cancer was effective and was 
well tolerated as a first-line chemotherapy. However, further phase III studies to 
investigate first-line regimens should be encouraged, and the relationship between 




Table 1. Characteristics of patients 
Characteristic  Patients (n = 15) 
Sex  
Male 10  (66.7) 
Female  05 (33.3) 
Age, years; median (range)  70 (53–79) 
ECOG performance status   
0 12  (80.0) 
1  03 (20.0) 
2  00 
Location of primary tumor   
Gallbladder  08 (53.3) 
Intrahepatic bile duct  02 (13.3) 
Extrahepatic bile duct  04 (26.7) 
Ampulla of Vater  01 (6.7) 
Disease status   
Locally advanced  03 (20.0) 
Metastatic  07 (46.7) 
Reccurent  05 (33.3) 
Prior resection   
Yes 12  (80.0) 
No  03 (20.0) 
Values are n (%) unless indicated otherwise. 
 
  










Table 2. Tumor response 
Site of lesion  Response rate  0Disease control rate 
Overall 26.7  0073.4 
Gallbladder 25.0  0062.5 
Intrahepatic bile duct  00  0100 
Extrahepatic bile duct  50.0  0100 
Ampulla of Vater  00  0100 






Fig. 1. OS curves of patients with advanced biliary tract cancer and gallbladder cancer; the OS curve 






Fig. 2. PFS curves of patients with advanced biliary tract cancer and gallbladder cancer; the PFS curve 
for patients with non-gallbladder cancer has not yet been reached. 
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